258 results on '"Tantravahi, Srinivas K."'
Search Results
2. Modified Delphi panel consensus recommendations for management of severe aplastic anemia
3. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
4. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
5. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations
6. Genomic landscape of myeloproliferative neoplasms
7. In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
8. HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice
9. Myeloma
10. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies
11. Abstract CT261: A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis
12. Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
13. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance
14. Minimal Residual Disease Eradication in CML: Does It Really Matter?
15. First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium
16. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
17. Primary Non-Hodgkin Lymphoma of the Ovary
18. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma
19. Concerto (NCT04409639): A Phase 2 Trial of Cobimetinib in Newly Diagnosed and HMA-Treated CMML Patients with RAS Pathway Mutations
20. Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores
21. Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
22. Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A National Analysis of Overall Survival and Demographic Features
23. Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study
24. Racial and Ethnic Disparities in Survival Outcomes in Chronic Myeloid Leukemia
25. Development of a Comprehensive Program for Evaluation of Hereditary Predisposition to Hematologic Malignancies
26. A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis
27. Trends in Frontline Treatment and Overall Survival in the Era of Targeted Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
28. Impact of academic medical center access on outcomes in multiple myeloma
29. MPN-527 Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-κB and Activation of P53 Pathways
30. MPN-112 Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
31. Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-κB and Activation of P53 Pathways
32. Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
33. Genome‐wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia
34. Abstract LB108: Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy
35. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
36. A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm
37. Addition of Navitoclax to Ongoing Ruxolitinib for Patients with Myelofibrosis: Subgroup Analysis of Molecular Biomarkers in the Phase 2 Study (REFINE)
38. Impact of academic medical center access on outcomes in multiple myeloma.
39. Integrating Emerging Science into Clinical Practice: Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer
40. A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors
41. Disease Characteristics of AML Patients with Germline DDX41 Variants
42. Multiple Myeloma Patients Treated at Academic Centers Have Improved Survival Outcomes
43. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
44. Systemic mastocytosis in a patient with Cowden syndrome
45. HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice
46. Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors
47. Exploratory Study on Impact of Comorbid Sleep Apnea Treatment in Patients with Polycythemia Vera and Essential Thrombocythemia
48. Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
49. Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification
50. An Inherited Disorder With Splenomegaly, Cytopenias, and Vision Loss
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.